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Abstract 
Infection with the dengue virus is currently clinically detected according to different biomarkers 
in human blood plasma, commonly measured by enzyme linked immunosorbent assays, including 
non-structural proteins (Ns1), immunoglobulin M (IgM) and immunoglobulin G (IgG). However, 
there is little or no mutual correlation between the biomarkers, as demonstrated in this study by a 
comparison of their levels in samples from 17 patients. As an alternative, the label free, rapid 
screening technique, Raman spectroscopy has been used for the characterisation/diagnosis of 
healthy and dengue infected human blood plasma samples. In dengue positive samples, changes 
in specific Raman spectral bands associated with lipidic and amino acid/protein content are 
observed and assigned based on literature and these features can be considered as markers 
associated with dengue development. Based on the spectroscopic analysis of the current, albeit 
limited, cohort of samples, Principal Components Analysis (PCA) coupled Factorial Discriminant 
Analysis, yielded values of 97.95% sensitivity and 95.40% specificity for identification of dengue 
infection. Furthermore, in a comparison of the normal samples to the patient samples which scored 
low for only one of the biomarker tests, but high or medium for either or both of the other two, 
PCA-FDA demonstrated a sensitivity of 97.38 % and specificity of 86.18 %, thus providing an 
unambiguous screening technology. 
 
Keywords: dengue infection; blood plasma, blood plasma biomarkers, Raman spectroscopy; 
Principal components analysis; Factorial Discriminant analysis; 
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Introduction 
Dengue disease has become a serious health concern, affecting millions of people worldwide every 
year. According to the WHO [1], about 3.97 billion people live in dengue pandemic tropical areas, 
and annually 400 million are infected, 96 million present clinically and 20,000 die of the disease. 
In Pakistan, 539 deaths having been reported in the last 12 years, 55,946 persons were found to be 
infected and 60% of cases are thought not to be reported. Dengue is a mosquito bite infection 
transmitted by one of the four dengue virus serotypes [2]. It is spreading more quickly in urban 
and semi urban areas and has become a serious health problem [3]. In some cases, the disease 
develops into severe DSS (dengue shock syndrome) or DHF (dengue hemorrhagic fever), resulting 
in bleeding leading to thrombocytopenia, loss of blood plasma, and severely low blood pressure. 
Children (≤15 years) are more severely infected than adults by dengue in Asia [3-6]. 
Dengue viruses contain a single strand of RNA of flavivirus [7] and produce new viral strands, 
translated and duplicated after infection. The non-structural proteins (Ns1) in the flavivirus 
regulate the duplication procedure of viral RNA [8]. The Ns1 proteins circulate in the blood plasma 
of dengue infected patients after the onset of symptoms of dengue fever for the first few days [9] 
and hence can be considered a viable biomarker for the diagnosis of disease by PCR (polymerase 
chain reaction) and ELISA (enzyme linked immunosorbent assay) in the early stage of infection 
[10-11]. 
Acute dengue infection can be confirmed by the presence of IgM (immunoglobulin M), while 
secondary dengue virus infection is indicated by the presence of IgG (immunoglobulin G) and 
both are also monitored by ELISA. Notably, the presence of IgM in a sample can indicate early 
stage infection, whereas the presence of elevated IgG levels, with normal IgM values, leads to the 
conclusion that dengue infection has occurred in the past [12]. 
In the early stages, a comprehensive analysis of dengue infection or biochemical changes produced 
by the dengue virus is of significant value for the diagnosis of dengue and its prevention. Although 
the treatment of dengue is only symptomatic, because there is no specific cure available for it [13], 
efficient and accurate diagnosis of the disease is important for clinical care which includes early 
detection of severe cases, case confirmation as well as differential diagnosis with other infectious 
diseases. Moreover, early diagnosis may also be required for outbreak control, pathogenesis, 
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academic research, vaccine development, and clinical trials [14]. There are many diagnostic 
methods already used in clinical practice, based on the detection of RNA, antibodies in serological 
tests and virus isolation in cell culture etc. [15-16]. The most common clinically employed 
diagnostic methods for dengue detection are ELISA and PCR, which has higher specificity and 
sensitivity, but these modalities are usually complex, lengthy and costly. Moreover, for the 
detection of Ns1, IgG and IgM, separate methods/tests are used. It is a most challenging task to 
diagnose infection with the dengue virus in the initial stages of dengue attack, essential to prevent 
a pandemic, and for recovery of the patient. Where rapid detection is required, compromise has to 
be made on specificity and sensitivity. 
Raman spectroscopy has been proven in recent years to be a highly sensitive and specific technique 
for the definition of biomedical changes produced in the body and diagnosis of different diseases 
[17-18]. It has been extensively employed over the past two decades for the characterisation of 
biological cells and tissue [19] and the influence of external agents on the cell [20-25]. Moreover, 
Raman spectroscopy has the capability to provide high content information, and even small 
changes in any of the biological macromolecules, including lipids, proteins and DNA, can be 
characterised simultaneously [26-28]. The Raman spectral changes which are identified could be 
helpful as diagnostic markers for the disease.  
Recently, viral infections such as human papilloma (HPV), Hepatitis C (HCV), dengue virus and 
many other diseases have been successfully monitored by Raman spectroscopy [29-32]. Khan et 
al. demonstrated the potential of Raman spectroscopy, coupled with support vector machine 
analysis, to diagnose dengue infection in human serum, based on positive IgM status, with a high 
degree of accuracy (85%) and precision (90%), and corresponding sensitivity and specificity of 
73% and 93%, respectively [33]. Bilal et al. performed a similar analysis, based on Partial Least 
Squares Regression analysis of Raman spectroscopic data of IgM positive and normal human 
serum samples, and using the receiver operating characteristic curve (ROC) approach, reported an 
accuracy of 96.67%, a sensitivity of 90% and a specificity of 100% [34]. However, in both studies, 
spectroscopic data was correlated with only one of the three common clinical biomarkers. 
In the present study, correlations between the levels Ns1, IgG and IgM positive blood plasma 
samples as measured using conventional ELISA kits, are compared and it is observed that there 
are few or no correlations. Raman spectroscopy, coupled with Principal Components Analysis 
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(PCA) is explored for differentiation between normal/healthy and Ns1, IgG and IgM positive blood 
plasma samples, which could pave the path for a more comprehensive monitoring of the stage of 
the infection by establishing specific Raman spectral features associated with these three markers 
of the disease. A combination of PCA and Factorial Discriminant Analysis (PCA-FDA) is 
employed to quantify the diagnostic potential of the technique. 
 
Materials and methods 
Sample preparation 
Blood plasma samples of 17 control (healthy volunteers) and 17 patients who presented with 
symptoms of dengue infection, were collected from Allied Hospital Faisalabad, Pakistan. All the 
blood plasma samples were handled according to the US NIH (National Institute of Health) 
recommendations. Quantitative serology of the 17 patient samples was performed to measure the 
levels of NS1 protein, IgG and IgM by using ELISA kits for dengue (Vircell Cat No. G1018, 
M1018). The outputs of the test kits are expressed in terms of optical density, and for this study, 
the cut off values for Ns1, IgM and IgG were 0.389, 0.378 and 0.384 respectively, as prescribed 
by the manual for the respective kits. In this regard, it is important to mention that these cut off 
values for the Ns1, IgM and IgG can be found only for the dengue infected patients and not for the 
healthy/control samples, as all the three biomarkers are associated specifically with the infection 
of the virus. The different values of Ns1, IgM and IgG, are shown in Table 1, along with their 
categorisation according to Normal, Medium and High levels of biomarker.  
Raman spectral acquisition 
To minimise any effects of heating due to residual absorbance in plasma at the laser wavelength 
of 785nm, a 20 μl drop of each plasma sample was placed on an aluminium slide at room 
temperature and Raman spectra were acquired before the plasma sample had dried. The process of 
placing the 20μl drop on the aluminium slide was repeated 3 times by employing a clean 
aluminium slide each time for acquiring 20-25 spectra in total from each sample. 
Raman spectral acquisition from all of the 17 healthy control and 17dengue infected blood plasma 
samples was performed using a Raman spectrometer (Peak Seeker Pro-785; Agiltron, USA). The 
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Peak Seeker Pro-785 utilizes a 785nm diode laser as the excitation source, delivering a laser power 
of ~60 mW at the sample. The laser was delivered to the sample through a 10× objective. The 
acquisition of the Raman spectra for all the samples was executed from 600 to 1800 cm-1and 20–
25 Raman spectra per sample were acquired with an acquisition time of 30 second. 
 
Dengue 
Sample 
Ns1 values Ns1 Cut-
off(0.389) 
IgM values IgM Cut-
off(0.378) 
IgG values IgG Cut-
off(0.384) 
D1 2.993 High 0.35 Low 0.136 Low 
D2 3.602 High 0.251 Low 2.013 High 
D3 2.727 High 0.143 Low 1.173 High 
D4 2.634 Medium 0.155 Low 0.161 Low 
D5 0.205 Low 0.88 Medium 1.274 High 
D6 0.1 Low 1.252 High 1.997 High 
D7 2.751 Medium 1.827 High 0.83 Low 
D8 2.996 High 0.144 Low 0.136 Low 
D9 2.786 High 0.727 Medium 0.823 Medium 
D10 2.751 High 0.247 Low 1.212 High 
D11 0.967 Medium 1.038 High 0.167 Low 
D12 0.016 Low 0.046 Low 0.633 Medium 
D13 0.125 Low 0.18 Low 0.145 Low 
D14 2.93 High 0.173 Low 0.191 Low 
D15 2.625 Medium 0.486 Medium 0.578 Medium 
D16 1.19 Medium 0.117 High 0.118 Low 
D17 2.786 High 0.25 Low 0.365 Low 
 
Table 1: Details of dengue samples and their different serologically determined values of the 
biomarkers Ns1, IgM and IgG. Numbers in (brackets) define the clinical cut off between normal 
and infected. For the purpose of this study, the latter categories are further differentiated according 
to “Medium” and “High” biomarker levels. 
 
Data pre-processing 
All data processing of the Raman spectra was performed using MatLab 7.8 and established 
protocols [26]. Data pre-processing included baseline correction, smoothing, vector normalisation, 
and substrate removal. All spectra, including substrate backgrounds, were vector normalised and 
smoothed using a Savitzky–Golay smoothing method (order 3, 17 point window). A rubber band 
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correction for baseline removal for all the spectra was carried out and the substrate spectra were 
subtracted from each spectrum. 
Data analysis 
The Raman spectral features were analysed by comparing the mean Raman spectra of dengue 
infected blood plasma samples with healthy ones. The assignments of the Raman spectral features 
used in interpretation of the results were taken from the literature [25, 35-38] and are described in 
Table 2. In order to further elucidate the biochemical basis of the development of dengue as 
compared with the healthy/control samples, PCA was performed. PCA is a mathematical 
procedure involving the transformation of possibly correlated variables into a smaller number of 
uncorrelated variables, known as principal components (PC), basically to reduce the 
dimensionality of the data whilst maintaining their variability. The first principal component 
accounts for the dominant source of variability in the data, and each succeeding principal 
component accounts for the next highest source of the remaining variability. The loadings of the 
PC can be understood as the orthogonal dimensions of biochemical differences which facilitate 
separation of different groups of spectra of Raman data along their variability as each spectrum 
scores along these dimensions. 
PCA was employed in this study to highlight the variability existing in the spectral data set 
recorded for the different tests of the dengue infection, and to differentiate their spectroscopic 
signatures. PCA-FDA was employed to further discriminate spectra based on the levels of the 
markers of dengue infection, such as IgG, demonstrating the diagnostic potential of the technique. 
Supervised learning methods such as discriminant analyses enable classification of unknown 
samples using prior knowledge of the category from training sets. To predict the qualitative 
affiliation of data points to a defined group (for instance level of the dengue antibody IgG), the 
coupling of PCA with Factorial Discriminant Analysis (PCA-FDA) exploits the calculated PC 
scores to better evaluate the discrimination rate achieved based on a data set [39].In the present 
study, leave one patient out strategy has been employed to discriminate between healthy and 
dengue blood plasma. The classification values obtained for each iteration have been gathered to 
deliver an overall confusion matrix representative of the data discrimination. For this type of 
strategy, the model is restricted to a specified number of iteration, dictated by the number of 
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patients. In present study, there are 34 groups of spectra (17 healthy and 17 dengue). Thus, in each 
iteration, one is patient taken out as validation and the 33 remaining are used as calibration.  
 
Peak cm-1 Assignment 
608 Cholesterol 
656 Protiens(L-histidine) 
688 Glycine 
708 Tryptophan 
802 Uracil-based ring breathing mode 
828 Proline, hydroxyproline, tyrosine, v2PO2
-  stretch of nucleic acids 
849 Most probably due to single-bond stretching vibration for the amino acids and 
valine and polysaccharides. Also assigned to proline, tyrosine, tryptophan-IgG 
875 Antisymmetric stretch vibration of choline group N+(CH3)3 , characteristic of 
phospholipids 
880 Tryptophan 
1102 O-P-O backbone stretch of DNA 
1164 C-H bending tyrosine 
1239 Amide III and CH2  wagging vibration from glycine backbone and proline side 
chains 
1297 Lipids/Palmitic acid 
1317 Guanine (B, Z-marker) 
1343 CH3, CH 2 wagging (collagen assignment) Glucose 
1491 C-N stretching vibration coupled with the in-plane C-H bending in amino 
radical cations 
1507 N-H bending 
1540 Amide carbonyl group vibration and aromatic hydrogens 
1587 Phenylalanine, Haemoglobin 
1640 Amide I band (protein band), C=O coupled to δ NH2 in plane 
1680 Amide I band (protein band) 
1719 Lipid 
1736 C=O ester (lipids) 
 
Table 2: Raman spectral peaks observed in the Raman spectra of healthy and dengue infected 
blood plasma samples. 
 
Results and Discussion 
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Figure 1 plots the ELISA based serology results of all three biomarkers for all samples, 
demonstrating that there is no clear correlation between the relative levels of the different 
biomarkers across the sample set. As can also be seen from Table 1, there are many instances of 
high levels of one biomarker, and normal levels of one or both of the other two. The serology 
biomarkers are therefore not an unambiguous diagnostic test for the presence of dengue infection. 
Ns1 is an antigen while IgG and IgM are antibodies and their serological levels in plasma depend 
on the day of the infection, as antigen (Ns1) can be detected 4-5 days after infection and antibodies 
including IgM are detectable 3-5 days after infection, but are undetectable after 2-3 month, while 
IgG is detectable after one week to several months [40-42].  
Figure 2 shows the mean Raman spectra of the healthy (control) and dengue infected blood plasma 
samples. The major differences in the Raman spectral features are labelled as vertical lines, and 
are assigned in Table 2. These spectral features can be considered as Raman spectral markers of 
biochemical changes associated with the dengue infection. Increases are seen in bands associated 
with the lipidic contents including 608cm-1, 875cm-1, 1297cm-1, 1719 cm-1 and 1736 cm-1. Notably, 
in the literature [38] these bands are associated specifically as cholesterol (608cm-1), choline 
(875cm-1), palmitic acid (1297cm-1), glutamic acid (1719 cm-1) and ester groups (1736 cm-1), 
indicating an increase in lipidic content in dengue infected samples. The lipids provide sites for 
the virus to attach, and hence a high concentration of lipids in dengue infected blood plasma can 
be associated with the dengue infection [43]. Furthermore, the complement-fixing of antibodies 
IgM is greater for higher amount of cholesterol and the Raman feature at 608 cm-1 is consistent 
with a high concentration of cholesterol (lipids) in the Raman spectra of dengue samples, so this 
peak may be associated with the greater complement fixing of the IgM and hence development of 
the dengue disease [44]. 
Raman spectral features associated with proteins are also observed as prominent differentiating 
factors. The peak intensity of the feature at 1239 cm-1(amide III (CH2 wagging vibration)) is greater 
in the mean Raman spectra of dengue infected blood plasma. This has previously been associated 
with IgM [45]. There is also an increase in the intensity at 1409 cm-1 in dengue infected samples 
which can be associated with the IgG antibody (IgG (vsCOO
-1). The Raman spectral features at 
"608 (lipids), 688 (glycine), 708 (tryptophan), 1164 (C-H bending), 1297 (lipids), 1507 (protein 
A), 1640 and 1680 (amide-I) and 1719 cm-1 (lipids) are observed with significantly higher 
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intensities in dengue positive samples as compared to dengue negative samples/healthy ones and 
are also associated with proteins. Notably, although the samples were measured in their wet state, 
the characteristic, but weak, water feature at ~1640cm-1 is not apparent in the spectrum of the 
control. 
Other spectral features associated with proteins include those at 880(tryptophan), 656(L-histidine) 
and 1164(tyrosine), 1102(amide III of proteins), 1343(CH3, CH2 wagging), 1587(haemoglobin) 
and 1317 cm-1 (C-H deformation), and have higher intensity in dengue infected blood plasma 
samples than in healthy volunteers.  
Notably, the Raman spectral features at 828 and 849cm-1, associated with out of plane tyrosine 
ring breathing [46], have higher intensity in the mean Raman spectra of healthy than dengue 
infected samples. A small peak evident with higher intensity in dengue infected spectra at 1491 
cm-1 is due the C-N stretching vibration coupled with the in plane C-H bending in amino radical 
cations. The peak at 1507 cm-1, again present with significantly higher intensity in the mean Raman 
spectra of dengue infected blood plasma, is due to N-H bending and has been reported for lysine 
present in protein A [47], which strongly binds IgG and makes variable binding with IgM [48]. 
The small peak at 1540 cm-1 which is significant in the dengue infected blood plasma is the Raman 
feature of the amide carbonyl group vibration and aromatic hydrogen and it has been reported that 
this peak is associated with the non structural protein (Ns1) [49]. The prominence of proteins in 
the Raman spectral data of dengue infected blood plasma can therefore be associated with the 
presence of dengue virus. 
Figure 3 (a) presents the PCA scatter plot of Raman spectral data of blood plasma of healthy 
volunteers versus those of dengue patients, in which dengue infected spectra are clustered in the 
positive side of x-axis, indicated by red dots and healthy blood plasma spectra are negative, shown 
by blue dots. A reasonably good separation of the datasets is indicated according to the 1stprinciple 
component (PC1 -77.42% of variance). The PCA loading associated with PC1 is shown in Figure 
3 (b), in which the positive loadings can be associated with the Raman spectral data clustered in 
the positive axis of the PC-1 and the negative loadings can be associated with the Raman spectral 
data clustered in the negative side of the x-axis [50].The major features of the PCA loading plot 
are almost the same as the differences observed in the Raman mean spectra of healthy verses 
dengue (Figure 1). The PCA loading plot shows differences at 608, 1297, 1409, 1719 and 1736 
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cm-1, also found in the mean Raman spectra of dengue infected blood plasma. These are the Raman 
features for lipids which can be associated with the anti-bodies (IgM and IgG) produced against 
infection. Similarly, the differences at 880, 1239, 1491, 1507, 1540, 1640, and 1680 cm-1 in the 
PCA loadings plot on the positive x-axis of PC-1 are the Raman signals for proteins. These features 
may be considered as identification markers of dengue virus infection and have been reported at 
1540 cm-1 for Ns1 in earlier research [49]. So, it can be extrapolated that other Raman spectral 
features like 880, 1491, 1507, 1640, and 1680 cm-1 may also be indication of dengue virus 
infection. 
As shown in Figure 1, there is little or no correlation between the levels of the three biomarkers, 
as determined by ELISA. Similarly, the distribution of the Raman spectra in the PCA of the dengue 
samples versus control shows no correlation with biomarker levels, as indicated in the 
Supplemental Material, Figures S1-3. Notably, samples with low levels of biomarkers are often 
well discriminated from the controls, indicating that Raman Spectroscopic analysis provides a 
more holistic analysis of the biochemical content of the blood sample. 
In order to quantify the diagnostic potential of the spectroscopic technique, a further classification 
of the control and dengue groups using PCA-FDA was carried out. The results are shown in Table 
3, which indicates that, based on the spectroscopic analysis of the current, albeit limited, cohort of 
samples, Principal Components Analysis (PCA) coupled with Factorial Discriminant Analysis, 
values of 97.95% sensitivity and 95.40% specificity for identification of dengue infection can be 
achieved., which is comparable with the sensitivity of 98% and specificity of 100% of dengue kit, 
as quoted on the dengue-kit used for the current study (Vircell Cat No. G1018, M1018). 
Notably, however, each test needs to be performed separately and independently for each sample, 
and is thus more demanding on consumables and therefore cost, whereas the Raman assay is label 
free, and simply requires the plasma from the blood of the dengue patients. 
 
 Dengue Normal Total/group Specificity 
Dengue 383 16 391 95.40% 
12 
 
Normal 8 332 348 Sensitivity 
  Total spectra 739 97.95% 
  
Table 3: Results of the PCA-FDA for the Raman spectral data of dengue positive and normal 
blood plasma samples. 
 
Performed individually, any one of the ELISA based biomarker tests can indicate low levels of 
infection, whereas another of the tests indicates high. For the example of IgM screening of the 
patient cohort represented in Table 1, 7 patients are diagnosed as “Low”, for which the other two 
tests yield a value of “high” or “medium”, indicating a sensitivity of this test alone of as low as 
63%. As a further demonstration of the potential of a Raman based assay, the control samples were 
compared with those samples which registered low for only one biomarker, but not the other two, 
by employing PCA and PCA-FDA. The samples selected in this way thus include Low Ns1 (D5, 
D6), Low IgM (D2, D3, D10) and Low IgG (D7, D11, D16) (Table 1). 
 
Figure 4 shows the PCA scatter plot of the Raman spectral data of control, versus the reduced 
dataset of blood plasma samples from dengue patients. There is reasonably good separation of the 
controls versus low levels of these three biomarkers of dengue by PC-1 (80.36 %). Notably, as all 
the three biomarkers are uncorrelated with each other as the samples which have low levels of one 
biomarker may have medium or high levels of other biomarker, they do not appear here as separate 
clusters in the PCA scatter plot. PCA-FDA results, for the comparison of Normal samples with the 
dataset of all lows mixed (Ns1, IgM and IgG) are shown in Table 4, which indicates that the 
presence of dengue infection in blood samples can be identified with a sensitivity of 97.38% and 
a specificity of 86.18%, in samples for which one of the biomarkers scored low. 
 
 Dengue 
(All lows) 
Normal Total/group Specificity 
13 
 
Dengue 
(All lows) 
186 5 191 86.18% 
Normal 47 293 340 Sensitivity 
  Total spectra 
 
531 97.38% 
  
Table 4: Results of the PCA-FDA for the Raman spectral data of Normal versus all lows mixed 
(Ns1,IgM and IgG) samples. 
Conclusions: 
The potential of Raman spectroscopy for the diagnosis and characterisation of healthy and dengue 
infected human blood plasma samples has been demonstrated. The spectral analysis indicates that 
distinct Raman spectral features are observed in the dengue positive samples, potentially 
associated with the development of the disease, as compared to the healthy samples. These Raman 
spectral features hence can be considered as markers of the dengue development and can be helpful 
for the diagnosis of the disease. Multivariate analysis with PCA and PCA-FDA enables a more 
precise identification of these spectral markers, and also allows a quantification of the diagnostic 
potential. Notably, as the Raman analysis is not based specifically on an individual biomarker, it 
provides a more holistic view of the biochemical content of the sample, and abnormalities 
associated with the disease. Critically, it identifies the presence of the disease in samples for which 
at least one of the biomarker tests indicated low levels, and thus can be considered an alternative 
for improved, unambiguous screening. 
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